Clinical trials: Leukemia, Acute
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
This is the study to test combination regimen of Nilotinib and Ruxolitinib therapy for the treatment of patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who is resistant to…
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT01914484
- Testing
- Nilotinib, Ruxolitinib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Myelofibrosis, Acute Lymphocytic Leukemia (ALL)
Expanded Access to Navitoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Myelofibrosis, Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma
- Trial name
- NCT03592576
- Testing
- Navitoclax, Venetoclax
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is highly heterogeneous, the efficacy of the individual varies greatly, and the risk of recurrence is high.
- Trial name
- NCT05330364
- Testing
- Chidamide, Cladribine
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Ge Zheng
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
- Conditions
- B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05281809
- Testing
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Lister
Bloodstream Infection, Acute Myeloid Leukemia
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia
There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia.
- Conditions
- Bloodstream Infection, Acute Myeloid Leukemia, Febrile Neutropenia
- Trial name
- NCT04910698
- Testing
- Antibiotic
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Poitiers University Hospital
Acute Pain, Pediatric ALL
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
This study aims to use functional near-infrared spectroscopy (fNIRS) to identify and quantify pain biomarkers during burn dressing changes and pain relief induced by virtual reality (VR).
- Conditions
- Acute Pain, Pediatric ALL, Procedural Pain, Burns
- Trial name
- NCT06303687
- Testing
- VR-PAT
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Nationwide Children's Hospital
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how…
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT00674193
- Testing
- pharmacological study, laboratory biomarker analysis
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons.
- Trial name
- NCT06626633
- Testing
- CRD3874
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with Acute myeloid leukemia (AML)/secondary AML…
- Trial name
- NCT04623216
- Testing
- Sabatolimab, Azacitidine
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.
- Trial name
- AMLCG 2008 (NCT01382147)
- Testing
- Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
- Where
- 32 sites in Germany
- Volunteers
- 396 people
- Sponsor
- Prof. Dr. Wolfgang Hiddemann
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation
This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.
- Trial name
- NCT00795548
- Testing
- 5-Azacitidine
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
The Registry MDS is an ongoing, observational study that has collected longitudinal data on diagnostics, demographics, clinical parameters, and health Care Interventions (HCI) from patients with MDS and therapy-related acute…
- Trial name
- NCT06956755
- Where
- France
- Volunteers
- 6,990 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myeloid Leukemia
Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
The primary goal of the study is to show that the treatment-related mortality of allogeneic hematopoietic stem cell transplantation an be significantly reduced by using a combination of 8 Gy total-body-irradiation and fludarabine…
- Trial name
- NCT00150878
- Testing
- Conditioning therapy
- Where
- Germany
- Volunteers
- 198 people
- Sponsor
- University Hospital Carl Gustav Carus
Leukemia
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to them, without harming normal cells.
- Trial name
- NCT00002609
- Testing
- lintuzumab, cytarabine, idarubicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
The purpose of this study is to determine whether 5-Azacytidine priming before the conditioning regimen for subjects receiving a hematopoietic stem cell transplant is an effective treatment for high risk myeloid malignancies in…
- Trial name
- NCT02497404
- Testing
- 5-Azacytidine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Weill Medical College of Cornell University
Leukemia, Myeloid, Acute
A Long-term Follow-up Study of Patients Who Received VOR33
VOR33 long-term follow-up (LTFU) study
- Trial name
- NCT05309733
- Testing
- VOR33
- Where
- 11 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- Vor Biopharma
AML
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
In this open-label, randomized, prospective clinical trial, nucleophosmin-1(NPM1) mutated acute myeloid leukemia (AML) patients who have reached CR are randomized into two groups.The control group receive high-dose…
- Trial name
- NCT03031249
- Testing
- Cytarabine, all-trans retinoic acid, Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China